Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2019 | Aberrrant transcriptional programming in AML

Constanze Bonifer • 8 Nov 2019
NCRI 2019
Acute Myeloid Leukemia Leukemia

Constanze Bonifer, PhD, University of Birmingham, Birmingham, UK, talks about sub-type specific aberrant transcriptional programming in acute myeloid leukemia (AML). Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Constanze Bonifer

3:48
The impact of various chromosomal abnormalities observed in AML & insights into RUNX1-ETO
Constanze Bonifer • 16 Mar 2023
3:15
The impact of CEBPA mutations & insights into the gene regulatory network of CEBPA-double mutant AML
Constanze Bonifer • 16 Mar 2023
4:09
Using transcriptional network analysis to better understand AML development and evolution
Constanze Bonifer • 16 Mar 2023
3:18
The molecular impact of RUNX1 mutations in AML
Constanze Bonifer • 16 Mar 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals